BioSpace News Archive

Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the company has secured USD $8 million from prominent Swedish real estate investor Erik Selin through his private company, Erik Selin Fastigheter AB.

Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference in a fireside chat hosted by Kristen Kluska, Director, Equity Research on September 27th, 2021.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri™, GRAIL’s groundbreaking multi-cancer early detection blood test.

Edesa Biotech, Inc. today announced positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.

Melinta Therapeutics today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was launched in July.

Allogene Therapeutics, Inc. today announced the appointment of Jae Park, M.D., acting Chief of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center in New York, to its Scientific Advisory Board (SAB).

Veru Inc. today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111)

Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and solutions company with comprehensive product offerings, today announced it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark covering the Company’s proprietary 3CL protease inhibitor oral antiviral drug candidate NLC-V-01, also known as Tollovir™.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) compared to standard of care (SoC) alone.

Humacyte, Inc. today announced the issuance of three additional U.S. patents covering its proprietary technology platform.